A

Alexion

Global biopharmaceuticals focusing on rare diseases

Executive Assistant & HR Representative

Full-TimeUpdated on 10/15/2026Deadline 10/31/26
No salary listed
Mid
Bachelor's
İstanbul, Türkiye
In Person
Administrative & Executive AssistanceExecutive Support

About the job

Requirements
  • A bachelor's degree in Human Resources, Business Administration, Management, or a related discipline.
  • Relevant experience in executive assistance, senior-level administrative support, HR operations, or a combined business support role.
  • Experience supporting a senior executive or leadership team.
  • Practical understanding of administrative processes and day-to-day human resources operations.
  • Ability to manage calendars, meetings, travel arrangements, correspondence, and multiple priorities.
  • Strong written and verbal communication skills in English and Turkish.
  • High level of discretion and integrity when handling confidential business and employee information.
  • Strong attention to detail, planning, organization, and follow-through.
  • Ability to work independently, exercise professional judgment, and recognize when escalation is required.
  • Strong proficiency in Microsoft Office applications and confidence in using HR, collaboration, and administrative systems.
  • Ability to communicate HR policies and processes clearly and professionally to employees and managers.
  • Strong stakeholder-management and interpersonal skills.
Responsibilities
  • Provide comprehensive administrative and organizational support to the General Manager, enabling effective management of business priorities.
  • Manage the General Manager’s calendar, appointments, meetings, and changing priorities, proactively identifying and resolving scheduling conflicts.
  • Coordinate internal and external meetings, leadership events, conferences, and business activities.
  • Arrange domestic and international travel, including transportation, accommodation, itineraries, and other logistical requirements.
  • Monitor and manage routine correspondence and inquiries, responding or redirecting requests as appropriate.
  • Prepare and coordinate documents and briefing materials required for leadership meetings and business reviews.
  • Handle confidential, sensitive, and business-critical information with discretion and sound judgment.
  • Act as a key liaison between the General Manager and internal teams, senior leaders, international colleagues, and external stakeholders.
  • Track decisions, commitments, and follow-up actions arising from meetings and leadership discussions.
  • Support the coordination of business projects and cross-functional initiatives as required.
  • Establish and maintain efficient administrative processes, filing systems, trackers, and working practices.
  • Independently organize and prioritize workload to ensure that deadlines are met and outputs are accurate.
  • Support the organization of employee meetings, leadership communications, town halls, and company events.
  • Support the day-to-day administration of local HR policies, processes, and employee programs in line with established guidelines.
  • Support communication between employees and managers regarding routine HR operational questions.
  • Support employee lifecycle activities such as onboarding, transfers, and offboarding.
  • Prepare and maintain HR documentation, employee correspondence, forms, trackers, and personnel records.
  • Support the timely and accurate collection of employee information required for payroll and benefits administration.
  • Coordinate with relevant internal teams and external providers to support payroll, compensation, benefits, and other HR operational processes.
  • Support recruitment administration, including interview coordination, candidate communication, documentation, and onboarding preparation.
  • Maintain accurate employee information in HR systems and support routine data-quality checks.
  • Help employees and managers understand applicable HR policies and processes, escalating complex or sensitive matters to the appropriate HR contact.
  • Identify administrative inefficiencies and recommend practical improvements to HR processes and employee services.
  • Support communication and administrative coordination during organizational changes.
  • Work closely with HR colleagues and line managers to ensure consistent and timely delivery of HR activities.
  • Ensure that personal data and confidential employee information are handled appropriately and securely.
  • Build effective working relationships across functions and organizational levels.
  • Demonstrate professionalism, responsiveness, and a service-oriented approach in all interactions.
  • Apply good judgment when resolving routine issues and escalate complex, sensitive, or high-risk matters appropriately.
  • Manage competing priorities in a fast-paced and changing business environment.
  • Contribute to an inclusive, collaborative, and positive workplace culture.
  • Perform other executive support or operational HR duties consistent with the purpose of the role.
Desired Qualifications
  • Previous experience in a multinational, matrixed, or highly regulated organization.
  • Experience supporting a General Manager, Country President, or equivalent senior leader.
  • Experience coordinating payroll inputs, benefits administration, recruitment, learning activities, or employee lifecycle processes.
  • Experience contributing to projects or process-improvement initiatives.
  • Relevant HR, business administration, or executive-assistance certification.
  • Experience working with international stakeholders.
  • Experience organizing leadership meetings, employee events, or company-wide communications.

About the company

Alexion focuses on discovering, developing, and selling therapies for rare and ultra-rare diseases by targeting the complement system. Its drugs, such as Soliris and Ultomiris, inhibit C5 to block inflammatory cascades, while Strensiq and Kanuma treat metabolic and lysosomal disorders. The company combines in-house R&D with acquisitions to expand its portfolio and leverages AstraZeneca’s global scale to reach patients. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to international markets at premium pricing.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1992

Get referred to Alexion

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AstraZeneca's July 2026 half-year revenue rose 9%, driven partly by Alexion's rare-disease growth.
  • Ultomiris gained FDA Priority Review on June 15, 2026 for IgAN, with Q4 2026 decision.
  • Koselugo's November 2025 adult NF1 approval and ALXN2220 phase 3 expand the pipeline.

What critics are saying

  • EmblemHealth's April 2025 Soliris antitrust suit targets patent settlements and biosimilar delays.
  • Soliris faces biosimilar erosion after March 2025, while Ultomiris still depends on C5-franchise switching.
  • Ultomiris carries meningococcal boxed warnings; a single fatal infection can trigger litigation and prescribing pullback.

What makes Alexion unique

  • Alexion pioneered complement biology, turning C5 inhibition into approved medicines since Soliris, 2007.
  • Ultomiris, Soliris, Strensiq, and Koselugo span hematology, nephrology, endocrinology, and oncology-adjacent rare diseases.
  • AstraZeneca's 2021 acquisition gives Alexion global commercialization scale and deeper trial funding.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Flexible Work Hours
  • Remote Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

StartupTicker
Apr 9th, 2024
Clinical Success For Neurimmune

Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases, has, in collaboration with its partner Alexion, advanced its drug candidate ALXN2220 into phase 3. This marks a significant step in the company’s journey to addressing the serious clinical condition ATTR-CM.  Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic clinical condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis. Despite recent advances in slowing disease progression, there is currently no treatment available to deplete cardiac ATTR amyloid and revert cardiac dysfunction. Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and ATTR cardiomyopathy, is currently testing a drug candidate, ALXN2220 (formerly NI006), a human antibody targeting ATTR Cardiomyopathy. In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, for ALXN2220. Neurimmune is responsible for completion of the phase 1b clinical study on behalf of Alexion, with Alexion incurring certain trial costs. Aside from the phase 1b trial, Alexion is responsible for further clinical development, manufacturing, and commercialization as ALXN2220. The two companies have now initiated the phase 3 of the DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 for the treatment of ATTR-CM

Business Wire
Apr 1st, 2024
Voydeya™ Approved In The Us As Add-On Therapy To Ravulizumab Or Eculizumab For Treatment Of Extravascular Hemolysis In Adults With The Rare Disease Pnh

WILMINGTON, Del.--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).1 VOYDEYA is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant EVH while treated with a C5 inhibitor.2,3. The approval by the US Food and Drug Administration (FDA) was based on positive results from the pivotal ALPHA Phase III trial. Results from the 12-week primary evaluation period of the trial were published in The Lancet Haematology.2. Bart Scott, MD, Professor, Division of Hematology and Oncology at the University of Washington Medical Center, and Professor, Clinical Research Division at Fred Hutchinson Cancer Center, said: “The approval of VOYDEYA offers this small subset of PNH patients an add-on therapy designed to address EVH, while maintaining disease control with ULTOMIRIS or SOLIRIS. Terminal complement inhibition with ULTOMIRIS can address the life-threatening complications of PNH, building on the efficacy and safety of SOLIRIS established over nearly 20 years.”

Business Wire
Mar 25th, 2024
Ultomiris® (Ravulizumab-Cwvz) Approved In The Us For The Treatment Of Adults With Neuromyelitis Optica Spectrum Disorder (Nmosd)

WILMINGTON, Del.--(BUSINESS WIRE)--ULTOMIRIS® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1. The approval by the US Food and Drug Administration (FDA) was based on positive results from the CHAMPION-NMOSD Phase III trial, which were published in the Annals of Neurology.2 In the trial, ULTOMIRIS was compared to an external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial. ULTOMIRIS met the primary endpoint of time to first on-trial relapse as confirmed by an independent adjudication committee. Zero relapses were observed among ULTOMIRIS patients with a median treatment duration of 73 weeks (relapse risk reduction: 98.6%, hazard ratio (95% CI): 0.014 (0.000, 0.103), p0.0001).2

PharmiWeb
Nov 28th, 2023
Nice Endorses Only Approved Treatment For Ultra-Rare Wolman Disease For Children Diagnosed Under The Age Of Two: Interview Opportunity

Sebelipase alfa (Kanuma®▼) recommended by NICE as the first treatment for infants with ultra-rare Wolman Disease.  . Kanuma, an enzyme replacement therapy, is the first medicine to be recommended for this life-threatening condition in infants under two years old